PTO/SB/25(09-04) 6. OMB 0651-0031 IT OF COMMERCE

## number.

	pproved for use through 07/31/2006. OMB 065 ademark Office; U.S. DEPARTMENT OF COMM			
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of i	nformation unless it displays a valid OMB control			
TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATEN   T     REJECTION OVER A PENDING "REFERENCE" APPLICATION	TING Docket Number (Optional) 03818/100L652-US1			
	03818/1002032-031			
In re Application of: Mladen Mercep et al.				
Application No.: 10/616,046				
Filed: July 8, 2003				
For: NOVEL COMPOUNDS, COMPOSITIONS AS CARRIERS FOR INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIV				
The owner*, Pliva Pharmaceutical Industry, Inc.	. of 100			
percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/615,716, filed on July 8, 2003, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.				
In making the above disclaimer, the owner does not disclaim the terminal part application that would extend to the expiration date of the full statutory term as defined it granted on said reference application, "as the term of any patent granted on said reference any terminal disclaimer filed prior to the grant of any patent on the pending reference application: expires for failure to pay a main found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole of 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any most of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	n 35 U.S.C. 154 and 173 of any patent ence application may be shortened by application," in the event that: any such attendance fee, is held unenforceable, is a terminally disclaimed under 37 CFR			
Check either box 1 or 2 below, if appropriate.				
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.				
I hereby declare that all statements made herein of my own knowledge are to information and belief are believed to be true; and further that these statements were may statements and the like so made are punishable by fine or imprisonment, or both, under States Code and that such willful false statements may jeopardize the validity of the applications.	ide with the knowledge that willful false Section 1001 of Title 18 of the United			
2. X The undersigned is an attorney or agent of record. Reg. No.	54.453			
De hololus Signature	12/8/04 Date			
, -				
Nicholas Sisti - 54,453				

Typed or printed name (212) 527-7700 Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

Express Mail Label No.	Dated:	 